Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

IMPORTANCE: Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and spectrum of chronic immune-related adverse events (irAEs) have not b...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Patrinely, J. Randall, Johnson, Rebecca, Lawless, Aleigha R., Bhave, Prachi, Sawyers, Amelia, Dimitrova, Maya, Yeoh, Hui Ling, Palmeri, Marisa, Ye, Fei, Fan, Run, Davis, Elizabeth J., Rapisuwon, Suthee, Long, Georgina V., Haydon, Andrew, Osman, Iman, Mehnert, Janice M., Carlino, Matteo S., Sullivan, Ryan J., Menzies, Alexander M., Johnson, Douglas B.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2021
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7995124/
https://ncbi.nlm.nih.gov/pubmed/33764387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.0051
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars